Ety Klinger

Ety Klinger started their work experience in 2006 as the Head of Development MS and AI Diseases at Teva Pharmaceutical Industries Ltd. They were then promoted to Senior Director in the same company in an unspecified role. In 2008, they joined Teva Pharmaceuticals as the Senior Director of Innovative R&D, and later assumed the roles of Vice President R&D at Proteologics in 2011 and Chief R&D Officer at MediWound in 2014. Additionally, there is a period in 2014 where Ety Klinger worked at home, but the specific role is not specified.

Ety Klinger holds an MBA degree from Northwestern University - Kellogg - Recanati School of Management (2008-2010). Ety also achieved a Ph.D. in Life Science and Biochemistry from Tel Aviv University (1989-1994), and another Ph.D. in Biochemistry from the same university (1988-1993). Furthermore, they obtained a Bachelor of Science (BSc) in Biology from The Hebrew University (1982-1985).